DSIP

About DSIP

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide that was first isolated from rabbit cerebral venous blood during induced sleep states. This unique neuropeptide consists of nine amino acids and has shown remarkable research potential in sleep regulation studies. DSIP works by modulating hypothalamic-pituitary function, particularly influencing corticotropin and somatotropin secretion pathways. Research has shown it's associated with enhanced delta-wave EEG activity and stress response modulation in laboratory models. Key studies have explored its role in circadian rhythm regulation, with findings suggesting potential applications in sleep disorder research and neuroendocrine investigations. The peptide exhibits stability across various pH conditions and demonstrates consistent biological activity in vitro. Our DSIP is supplied as a sterile lyophilised powder with >98% purity, verified through HPLC analysis. Each vial contains precisely measured quantities suitable for controlled laboratory experiments. The product maintains stability when stored at -20°C and reconstitutes readily in sterile water. It's ideal for researchers investigating sleep mechanisms, neuroendocrine pathways, and stress-response systems in controlled laboratory environments.

Research Applications

• Investigated for association with delta-wave EEG activity in sleep-research models
• Studied for modulation of corticotropin and somatotropin release in vitro
• Researched for influence on stress-response and HPA-axis biomarkers
• Associated with antioxidant activity in cellular oxidative-stress assays
• Investigated as a model nonapeptide for blood-brain-barrier transport research
• Studied for effects on circadian and chronobiological signalling pathways

Research Mechanism — DSIP

A simplified summary of what DSIP is studied for in research models. For laboratory in-vitro use only.

1. 1

   Molecular target

   DSIP has been studied for interactions with central nervous system targets including GABAergic and glutamatergic systems, although a single canonical receptor has not been definitively identified. Investigations have characterised binding to brain membrane fractions.

   • Putative modulation at GABA-A receptor complex
   • NMDA receptor-associated binding in brain homogenates
   • Hypothalamic membrane binding sites
2. 2

   Investigated pathways

   Preclinical studies have explored DSIP's role in delta-wave EEG activity, hypothalamic-pituitary-adrenal (HPA) axis modulation, and oxidative stress markers. Associated signalling involves CRH attenuation.

   • Reduction of CRH-driven ACTH release in HPA models
   • Modulation of cortical delta-frequency EEG activity
   • Antioxidant enzyme expression (SOD, catalase) in vitro
3. 3

   Preclinical research applications

   Preclinical studies have explored DSIP in rodent EEG sleep-architecture models and stress-paradigm investigations. Not approved for human use.

   • Rat polysomnographic EEG-recording studies
   • Murine restraint-stress HPA-axis models
   • In vitro neuronal oxidative-stress assays

For research use only. DSIP is not approved as a medicine in the UK and is not intended for human or veterinary administration. See the compliance page for full terms.